Harry Lampiris, MD
Professor Emeritus
Medicine
School of Medicine

Education & Training

Show all (3) Hide

• Post-Doc Fellow/Scholar School of Medicine University of California, San Francisco 1991
• M.D. School of Medicine University of California, San Francisco 1985
• Residency School of Medicine University of California, San Francisco

Interests

Show all (3) Hide

• Antiretroviral Therapy
• Antimicrobial Therapy
• Infectious Disease Clinical Education and Training

Websites

Show all (1) Hide

• Clinical Profile at UCSF Medical Center (ucsfhealth.org)

Publications (35)

Top publication keywords:
HIV Integrase InhibitorsEnzyme InhibitorsAdenineInfluenza A virusInfluenza, HumanDeoxycytidineQuinolonesHIV IntegraseHIV-1Antiviral AgentsNeuraminidaseCarbamatesHIV InfectionsThiazolesOrganophosphonates

• Association between household exposure and cycle threshold in COVID-19 infected health care workers.
  Journal of occupational medicine and toxicology (London, England) 2021 Chien A, Domeracki S, Guntur S, Taylor K, Lu CM, Lampiris H, Blanc PD
• Cycle Threshold to Test Positivity in COVID-19 for Return to Work Clearance in Health Care Workers.
  Journal of occupational and environmental medicine 2020 Domeracki S, Clapp RN, Taylor K, Lu CM, Lampiris H, Blanc PD
• Opportunistic coinfection with Pneumocystis jirovecii and Coccidioides immitis associated with idelalisib treatment in a patient with chronic lymphocytic leukaemia.
  BMJ case reports 2020 Ward LM, Peluso MJ, Budak JZ, Elicker BM, Chin-Hong PV, Lampiris H, Mulliken JS
• Response to: Is Burnout Infectious? Understanding Drivers of Burnout and Job Satisfaction Among Academic Infectious Diseases Physicians.
  Open forum infectious diseases 2020 Budak JZ, Brickman CE, Abdoler EA, Wallender EK, Mulliken JS, Kerkhoff AD, Lampiris H, Babik JM, Koss CA, Schwartz BS
• Evaluating the Concordance of Clinician Antiretroviral Prescribing Practices and HIV-ASSIST, an Online Clinical Decision Support Tool.
  Journal of general internal medicine 2019 Ramirez JA, Maddali MV, Budak JZ, Li JZ, Lampiris H, Shah M

Show all (30 more) Hide

• 2534. Development of an Infectious Diseases Fellowship Well-Being Program.
  Open Forum Infectious Diseases 2019 Jehan Budak, Cristina Brickman, Emily Abdoler, Erika Wallender, Jennifer S Mulliken, Andrew D Kerkhoff, Harry Lampiris, Jennifer M Babik, Catherine Koss, Brian Schwartz, Brian Schwartz
• HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing.
  Science translational medicine 2018 Yukl SA, Kaiser P, Kim P, Telwatte S, Joshi SK, Vu M, Lampiris H, Wong JK
• Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
  Nature medicine 2016 Li P, Kaiser P, Lampiris HW, Kim P, Yukl SA, Havlir DV, Greene WC, Wong JK
• Neuraminidase Inhibitors and Influenza Infection-Reply.
  JAMA internal medicine 2016 Louie JK, Lampiris H
• Treating Influenza With Neuraminidase Inhibitors: What Is the Evidence?
  JAMA internal medicine 2015 Louie JK, Lampiris H
• Geriatric Syndromes in Older HIV-Infected Adults.
  Journal of acquired immune deficiency syndromes (1999) 2015 Greene M, Covinsky KE, Valcour V, Miao Y, Madamba J, Lampiris H, Cenzer IS, Martin J, Deeks SG
• The Montreal Cognitive Assessment: A Pilot Study of a Brief Screening Tool for Mild and Moderate Cognitive Impairment in HIV-Positive Veterans.
  Journal of the International Association of Providers of AIDS Care 2014 Chartier M, Crouch PC, Tullis V, Catella S, Frawley E, Filanosky C, Carmody T, McQuaid J, Lampiris H, Wong JK
• Management of human immunodeficiency virus infection in advanced age.
  JAMA 2013 Greene M, Justice AC, Lampiris HW, Valcour V
• Su1471 Colorectal Neoplasia in HIV-Infected Individuals During Screening and Surveillance Colonoscopy.
  Gastrointestinal Endoscopy 2012 Ma Somsouk, Susie W. Ng, Rachel Kornfield, Kenneth R. McQuaid, Harry Lampiris, John M. Inadomi
• Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.
  Expert review of anti-infective therapy 2012 Lampiris HW
• Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.
  Journal of virological methods 2011 Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T, Pandori M, Havlir DV, Wong JK
• A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.
  The Journal of infectious diseases 2011 Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG
• CD4+ T cell reconstitution, T cell activation, and memory T cell subset composition in blood and gut of HIV-negative and ART-suppressed HIV-positive patients: implications for HIV persistence in the gut.
  Journal of the International AIDS Society 2010 S Yukl, E Sinclair, L Epling, Q Li, A Shergill, K McQuaid, L Duan, B Hare, H Lampiris, A Haase, D Havlir, J Wong
• The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
  Science (New York, N.Y.) 2010 International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge …
• Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.
  AIDS (London, England) 2010 Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, Pandori M, Sinclair E, Günthard HF, Fischer M, Wong JK, Havlir DV
• Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.
  The Journal of infectious diseases 2010 Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi AL, Girling V, Ho T, Li P, Fujimoto K, Lampiris H, Hare CB, Pandori M, Haase AT, Günthard HF, Fischer M, Shergill AK, McQuaid K, Havlir DV…
• Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.
  Journal of acquired immune deficiency syndromes (1999) 2010 Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R, Martin JN, Lalezari J, Bangsberg D, Petropoulos C, Deeks SG
• Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
  The Journal of infectious diseases 2010 Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, Kearney BP, Cheng AK
• Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy.
  Journal of neurovirology 2009 Cardenas VA, Meyerhoff DJ, Studholme C, Kornak J, Rothlind J, Lampiris H, Neuhaus J, Grant RM, Chao LL, Truran D, Weiner MW
• Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
  The New England journal of medicine 2008 Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne …
• Resolution of hepatitis C virus-induced steatosis improves tolerability of antiretroviral drugs associated with hepatotoxicity in an HIV-infected individual.
  The Journal of infectious diseases 2008 Shah T, Lampiris H, Vu M, Monto A, Tien PC
• Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.
  The Journal of infectious diseases 2008 Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG
• Covering all the bases: targeting HIV-1 integrase.
  Journal of acquired immune deficiency syndromes (1999) 2006 Wong JK, Lampiris H
• Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.
  The Journal of infectious diseases 2006 Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG
• The independent effect of drug resistance on T cell activation in HIV infection.
  AIDS (London, England) 2006 Hunt PW, Deeks SG, Bangsberg DR, Moss A, Sinclair E, Liegler T, Bates M, Tsao G, Lampiris H, Hoh R, Martin JN
• T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.
  The Journal of infectious diseases 2003 Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG
• Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002 Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B
• Streptococcus pneumoniae Transmission in Chronic-Care Facilities: Description of an Outbreak and Review of Management Strategies.
  Infection Control and Hospital Epidemiology 1998 Donald C. Sheppard, Kathleen A. Bartlett, Harry W. Lampiris
• Streptococcus pneumoniae transmission in chronic-care facilities: description of an outbreak and review of management strategies.
  Infection control and hospital epidemiology 1998 Sheppard DC, Bartlett KA, Lampiris HW
• Concomitant Cotrimoxazole (CTX) Does Not Affect Rifabutin (RBT) Kinetics in HIV+ Patients.
  Clinical Pharmacology & Therapeutics 1996 D. Colbom, H. Lampiris, B. Lee, R. Lewis, P. Sullam, P.K. Narang